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Abstract
Background: A minority of intra-abdominal desmoid tumors is associated with Gardner’s syndrome in which
desmoid tumors become an important cause of morbidity and mortality if they are surgically unresectable.
Case presentation: Here, we report two cases of intestinal perforation during chemotherapy in patients with
Gardner’s syndrome-associated intra-abdominal desmoids. One female and one male patients who developed
inoperable desmoids were given the chemotherapeutic regimen of doxorubicin plus dacarbazine, followed by
meloxicam. Significant tumor regression was observed clinically. However, intestinal perforation happened in both
patients. They were subjected to emergency surgery, follow-up management, and survived up to now.
Conclusions: The doxorubicin plus dacarbazine chemotherapy is an effective treatment for intra-abdominal demoid
tumors in patients with Gardner’s syndrome. On the other hand, given severe adverse events might occur, clinicians
should pay more attention that tumor quick regression may cause intestinal perforation in which urgent surgical
intervention is necessary.
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Background
Desmoid tumors (aggressive fibromatosis) are rare, lo-
cally aggressive, benign fibroblastic tumors, accounting
for ~0.03 % of all neoplasms. Although desmoid tumors
(DTs) are histologically benign and without any meta-
static potential, they are locally aggressive with a ten-
dency to invade nearby structures and recur after
resection. The etiology of these tumors is still controver-
sial, but antecedent trauma including surgery, endocrine,
and genetic factors seem to be implicated. Most des-
moids are sporadic, but some are in association with fa-
milial adenomatous polyposis (FAP), also known as
Gardner’s syndrome.
Although desmoid tumors can arise at any body site,
the desmoids in Gardner’s syndrome usually arise in the
abdomen and are a major cause of morbidity and mor-
tality in patients who undergone prophylactic colonic
surgery [1, 2]. Desmoids account for 10–14 % of deaths
of Gardner’s syndrome patients due to intestinal ob-
struction or perforation, making it the second leading
cause of death after colorectal carcinoma [3, 4].
Complete surgical removal remains the optimal treat-
ment for extra-abdominal and abdominal-wall desmoids
but is not recommended for mesenteric desmoids be-
cause of the high risk of recurrence and the difficulties
involved in the operation [5]. Besides, surgical excision
of intra-abdominal desmoids is hazardous, with a peri-
operative mortality rate of 10 to 60 % and can lead to
further tumor progression [6, 7]. Nonoperative therapies
include antiestrogen, nonsteroidal anti-inflammatory
drugs, chemotherapy, and targeted therapy. Here, we
evaluate the efficacy of a combination therapy of doxo-
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which was shown effective in patients with Gardner’s
syndrome not amenable to surgery [8–10].
Case presentation
Case 1
In 2009, a 35-year-old woman (patient 1) was diagnosed
as FAP, inherited from her father, with numerous aden-
omatous polyps at the surface of colon. She did not suf-
fer from osteomas of the skull, thyroid cancer, and
epidermoid cysts. The patient received prophylactic col-
ectomy. The patient presented with abdominal bloating
and self-palpable left abdominal mass in September
2012 (Fig 1a). Laparotomy showed multiple lumps, with
a maximum diameter of 12 cm, which adhered to the
abdominal organs. The diagnosis of abdominal mass bi-
opsy indicated desmoid tumors.
Multidisciplinary team (MDT) discussion indicated
that the tumors were unresectable. On Oct 11th 2012,
the patient was administrated with systemic chemother-
apy: doxorubicin (20 mg/m2 daily) plus DTIC (150 mg/
m2 daily) throughout 4 days of drip intravenous infusion
every 28 days, followed by meloxicam (10 mg/m2). The
abdominal bloating was relieved after 1 cycle of
chemotherapy. At the end of the second cycle of
chemotherapy, the patient felt abdominal pain and
fever. X-ray imaging displayed a little shadow of free
gas below the right diaphragm (Fig 1b). Blood test
showed WBC 22.6 × 109/L, N 89 %. The evidence in-
dicated bowel perforation. Benefit from the tumor
shrinkage, intestinal anastomosis and right lower ab-
dominal colostomy were successfully performed. The
patient was administrated with meloxicam (7.5 mg bid)
after the operation. The lesion remains without tumor
progression till now (Fig 1c, more than 40 months so far).
Case 2
A 16-year-old man was found to have multiple polyps by
colonoscopy and underwent left half colonic resection in
the out court in 2004. He was absent of gastric and
duodenal polyps, osteomas, and dermoid cysts. The pa-
tient underwent small bowel mesentery root palliative
resection, partial ileal resection, and anastomosis plus
marginal resection of associated desmoid tumors due to
the progression of DT and occurrence of small bowel
perforation in February 2014. The DT was enlarged fur-
ther and led to progressive abdominal pain. The patient
presented in our hospital with a great mass (maximum
section 18 cm × 13 cm) in abdomen and a desmoid
tumor on the left abdominal wall as evidenced by CT
scan in April 2014 (Fig 2a). After MDT discussion, the
patient was administrated with doxorubicin (20 mg/m2
daily) plus DTIC (150 mg/m2 daily) throughout 4 days
of drip intravenous infusion every 28 days, followed by
meloxicam (10 mg/m2) on May 24th 2014. After 3 cycles
of chemotherapy, abdominal pain symptoms of the pa-
tient were disappeared. After 5 cycles of chemotherapy,
the patient displayed abdominal pain and high fever with
elevated amount of neutrophils. CT scan showed intes-
tinal perforation which was not detected by the X-ray
(Fig 2b) and the tumor regression (the maximum section
of tumor 14 cm × 8 cm). The patient underwent tumor
shrinkage, drainage of focal infection, and intestinal
anastomosis. After operation, he was administrated with
meloxicam (7.5 mg bid). The treatment is ongoing, and
the lesion remains without tumor progression up to now
(more than 26 months so far).
Discussion
About 10 % of Gardner’s syndrome patients develop
mesenteric desmoids [11]. In contrast to sporadic DTs,
the majority of tumors in patients with Gardner’s syn-
drome present intra-abdominally. Surgery is the widely
accepted first-line treatment for extra-abdominal and
abdominal-wall desmoids but is not recommended for
intra-abdominal desmoids given the operational difficul-
ties and high risk of recurrence [12, 13]. American Soci-
ety of Colon and Rectal Surgeons therefore advocate
conservative management over initial resection for pa-
tients with Gardner’s syndrome or with large slowly
growing desmoids compromising the mesentery, vessels,
or adjacent organs [14, 15]. Both our patients developed
desmoid tumors after prophylactic colectomy of Gardner’s
Fig. 1 The progression of the intra-abdominal desmoid in patient 1. a CT scan before DOX/DTIC therapy showing a large mass in the abdomen
in October 2012. b X-ray imaging displayed the shadow of free gas (as indicated by the arrow) below the right diaphragm. c Follow-up CT scan
in February 2016
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syndrome and presented with abdominal symptoms
caused by the compression of the huge mass, indicating a
demand for clinical intervention.
Choosing optimal therapy for patients with Gardner’s
syndrome is difficult because the diagnosis is rare and
no randomized and prospective trials for different treat-
ment approaches are available. In addition, the evalu-
ation of efficacy is problematic given that desmoids have
a variable natural history, with some tumors showing
spontaneous regression in the absence of treatment.
Therefore, the treatment plans have to consider that the
growth of DT can be highly variable with growing,
stabilization, and even regression. Nonsteroidal anti-
inflammatory drugs (NSAIDs) and antiestrogens may be
used as first-line therapies for an unresectable tumor [16].
However, NSAIDs and hormone therapy have shown lim-
ited success in intra-abdominal desmoids [17, 18]. Cyto-
toxic chemotherapy is recently investigated for treating
such cases. It has been reported that cytotoxic-
chemotherapy benefits about 20 to 75 % of treated desmoid
patients [19]. Several studies indicated the efficacy and
safety of the chemotherapy regimen of doxorubicin and
dacarbazine combination in treating patients with Gard-
ner’s syndrome-associated desmoid tumors [8, 9, 20, 21].
Gega combined DOX, DTIC, and meloxicam in the treat-
ment of Gardner’s syndrome-associated desmoids and
achieved a great success with high rates of partial or
complete response [8]. Adapted the regimen applied by
Gega in our study, we observed the remission of symptom
in patient 1 and significant tumor shrinkage (partial re-
sponse) in patient 2, which supports the efficacy of this mo-
dality. Unexpectedly, bowel perforation happened in both
patients during the treatment. Postoperative pathology ana-
lyses showed necrosis of the desmoids. To our knowledge,
this is the first time to report such a drastic adverse event
resulting from DOX-DTIC-meloxicam in the treatment of
Gardner’s syndrome-associated desmoids. It is likely due to
the sensitivity to chemotherapy and acute necrosis of the
desmoids as indicated by significant tumor regression. For-
tunately, we were able to perform intestinal anastomosis in
time by the support of MDT. Patients recovered well from
the surgery and won the opportunity for further therapy.
Inhibited by chemotherapy, the fast growing tumor
became amenable to palliative surgery and the residual
tumor could be controlled by NASIDs. Alternatively,
we speculate that reduction of the dosage may elimin-
ate the adverse effect of DOX-DTIC-meloxicam. In
fact, Yamaoto employed low-dose DOX-DTIC therapy to
three patients against intra-abdominal desmoids, which
was a safe and effective regimen and permitted repeated
administration cycles (50 mg/m2 DOX and 600–700 mg/
m2 DTIC per cycle) up to 10–11 times [21].
Conclusions
In conclusion, we reported two cases of unresectable
intra-abdominal desmoid tumors associated with Gard-
ner’s syndrome. Our study provides further evidence of
the remarkable efficacy of the DOX-DTIC regimen.
However, the drastic regression of tumor upon DOX-
DTIC treatment resulted in the perforation of implicated
intestine. Even if there is no evidence of intestinal per-
foration in X-ray imaging during the management of
intra-abdominal desmoids complicating Gardner’s syn-
drome, oncologists should be aware of the possibility of
perforation when the patients have high fever and
abdominal pain. MDT discussion and team work may be
helpful. The modality of DOX-DTIC-meloxicam re-
quires further study on a clinical trial basis. We are also
trying a sequential chemotherapeutic regimen of DTIC
followed by doxorubicin plus NASID. New results are
expected in the near future.
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